Comparison of the Efficacy, Safety and Withdrawal of Alpidem and Alprazolam in Anxious Patients

1994 ◽  
Vol 165 (1) ◽  
pp. 94-100 ◽  
Author(s):  
Lodovico Frattola ◽  
Martine Garreau ◽  
Roberto Piolti ◽  
Sirio Bassi ◽  
Maria G. Albizzati ◽  
...  
Keyword(s):  
Anxiety Disorders ◽  
Active Treatment ◽  
Withdrawal Syndrome ◽  
Withdrawal Symptoms ◽  
Check List ◽  
Double Blind ◽  
General Anxiety ◽  
Symptom Check List ◽  
Withdrawal Phase ◽  
Made In

BackgroundWe investigated whether a new non-benzodiazepine anti-anxiety drug, alpidem, produces weaker withdrawal symptoms than alprazolam.MethodUnder a double-blind procedure, 122 patients suffering from general anxiety disorders were randomly allocated to either alpidem (50 mg, three times a day) or alprazolam (0.5 mg, three times a day) for six weeks, followed by a two-week placebo withdrawal phase. The diagnosis of withdrawal syndrome (WS) was made, in blind conditions, on the basis of the Withdrawal Symptom Check List (WSCL), after one or two weeks of discontinuation of active treatment.ResultsThe WS occurred significantly less frequently in the alpidem group (n = 10, 18%) than in the alprazolam group (n = 26, 48%). Typical withdrawal symptoms on the WSCL were also significantly less severe (P = 0.044) in the alpidem group compared with the alprazolam group.ConclusionsAlpidem may be a valid alternative to current benzodiazepine anxiolytic therapy because it produces fewer and weaker withdrawal symptoms than alprazolam and is better tolerated.

scholarly journals Evaluation Des Effets Secondaires Chez Les Nevrotiques - Un Essai Avec La Mesoridazine: Et Le Placebo

1975 ◽  
Vol 20 (1) ◽  
pp. 61-66 ◽  
Author(s):  
Y. D. Lapierre
Keyword(s):  
Side Effects ◽  
Active Drug ◽  
Effets Secondaires ◽  
Check List ◽  
Double Blind ◽  
Symptom Check List ◽  
Cardio Vascular

The incidence of side effects following administration of mésoridazine and placebo was studied in a neurotic outpatient population using an open questionnaire and a symptom check-list. Men on mésoridazine reported more side effects with a symptom check-list than on the questionnaire. This difference was not significant in women. More symptoms were elicited with a check-list while the patients were on the drug than by questioning. These side effects were mainly gastro-intestinal and were mild. Cardio-vascular symptoms were as frequent on placebo as on the active drug. After six weeks of double-blind administration there was no difference in the total number of side effects reported for placebo and for mésoridazine.

Beeinträchtigtes Erkennen emotionaler Gesichtsausdrücke durch psychiatrische Patientinnen bei Alexithymie

2013 ◽  
Vol 61 (1) ◽  
pp. 7-15 ◽  
Author(s):  
Daniel Dittrich ◽  
Gregor Domes ◽  
Susi Loebel ◽  
Christoph Berger ◽  
Carsten Spitzer ◽  
...  
Keyword(s):  
Emotion Recognition ◽  
Emotional Expression ◽  
Depression Scale ◽  
Facial Emotion Recognition ◽  
Facial Emotion ◽  
Check List ◽  
Psychosomatische Erkrankungen ◽  
Psychiatrische Patienten ◽  
Symptom Check List ◽  
Tas 20

Die vorliegende Studie untersucht die Hypothese eines mit Alexithymie assoziierten Defizits beim Erkennen emotionaler Gesichtsaudrücke an einer klinischen Population. Darüber hinaus werden Hypothesen zur Bedeutung spezifischer Emotionsqualitäten sowie zu Gender-Unterschieden getestet. 68 ambulante und stationäre psychiatrische Patienten (44 Frauen und 24 Männer) wurden mit der Toronto-Alexithymie-Skala (TAS-20), der Montgomery-Åsberg Depression Scale (MADRS), der Symptom-Check-List (SCL-90-R) und der Emotional Expression Multimorph Task (EEMT) untersucht. Als Stimuli des Gesichtererkennungsparadigmas dienten Gesichtsausdrücke von Basisemotionen nach Ekman und Friesen, die zu Sequenzen mit sich graduell steigernder Ausdrucksstärke angeordnet waren. Mittels multipler Regressionsanalyse untersuchten wir die Assoziation von TAS-20 Punktzahl und facial emotion recognition (FER). Während sich für die Gesamtstichprobe und den männlichen Stichprobenteil kein signifikanter Zusammenhang zwischen TAS-20-Punktzahl und FER zeigte, sahen wir im weiblichen Stichprobenteil durch die TAS-20 Punktzahl eine signifikante Prädiktion der Gesamtfehlerzahl (β = .38, t = 2.055, p < 0.05) und den Fehlern im Erkennen der Emotionen Wut und Ekel (Wut: β = .40, t = 2.240, p < 0.05, Ekel: β = .41, t = 2.214, p < 0.05). Für wütende Gesichter betrug die Varianzaufklärung durch die TAS-20-Punktzahl 13.3 %, für angeekelte Gesichter 19.7 %. Kein Zusammenhang bestand zwischen der Zeit, nach der die Probanden die emotionalen Sequenzen stoppten, um ihre Bewertung abzugeben (Antwortlatenz) und Alexithymie. Die Ergebnisse der Arbeit unterstützen das Vorliegen eines mit Alexithymie assoziierten Defizits im Erkennen emotionaler Gesichtsausdrücke bei weiblchen Probanden in einer heterogenen, klinischen Stichprobe. Dieses Defizit könnte die Schwierigkeiten Hochalexithymer im Bereich sozialer Interaktionen zumindest teilweise begründen und so eine Prädisposition für psychische sowie psychosomatische Erkrankungen erklären.

Évolution sous traitement d’un groupe de 128 états dépressifs suivis en médecine générale

1986 ◽  
Vol 1 (2) ◽  
pp. 162-169
Author(s):  
D. Cremniter ◽  
J.D. Guelfi ◽  
J. Fermanian
Keyword(s):  
Effets Secondaires ◽  
Check List ◽  
Médecine Générale ◽  
Médecins Généralistes ◽  
Symptom Check List ◽  
La Modification

Résumé128 états dépressifs (24 hommes et 104 femmes) ont été inclus dans cette étude par 11 médecins généralistes sur une période de 4 mois. L’évaluation initiale (EO) montrait que 92 % des patients relevaient du diagnostic d’état dépressif selon la liste des critères de Spitzer (RDC, 1977) dont 72 % de dépressions majeures et 20 % de dépressions mineures. La note obtenue à la MADRS (échelle de dépression de Montgomery et Asberg) à EO était supérieure à 20 chez les 3/4 des patients. La fréquence des traitements prescrits se répartissait ainsi : anxiolytiques (74.2 % des patients), antidépresseurs (68 %) et somnifères (22.6 %). Après 15 jours d’évolution sous traitement, 99 patients ont été revus lors de la 2ème évaluation (E1). La diminution des scores obtenus à la MADRS se situe entre 0 et 50% chez 54 patients et atteint plus de 50 % chez 32 patients. Le jugement global du généraliste confirme l’importance du taux d’amélioration portant sur 80 % des patients. Parmi ceux-ci, un degré marqué d’amélioration est retrouvé chez 45 % des déprimés traités par antidépresseurs alors qu’il n’est que de 22 % de ceux qui ne reçoivent pas ce traitement. Les effets secondaires sont présents chez 45 % des patients à E1. Chez ceux traités par les antidépresseurs, la fréquence de survenue de ces effets est nettement plus importante (43 %) que chez ceux qui ne reçoivent pas ce traitement (15 %).Au cours de l’évolution, la modification des scores de la HSCL (Hopkins Symptom Check-List) est mesurée chez 43 des patients revus lors de la 3ème évaluation (E2) un mois après le début du traitement. Les 7 dépressions majeures sont toutes améliorées. Sur les 30 dépressions majeures, la diminution des scores porte sur les 5/6 des patients.

EEG Synchronized TMS for Individualized Therapy in Major Depressive Disorder

2011 ◽  
Vol 26 (S2) ◽  
pp. 1144-1144
Author(s):  
Y. Jin ◽  
J. Phillips ◽  
Yueqin Huang ◽  
Steven Heurta
Keyword(s):  
Major Depressive Disorder ◽  
Side Effects ◽  
Depressive Disorder ◽  
Active Treatment ◽  
Rating Scale ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Stimulus Frequency ◽  
List Type ◽  
Major Depressive ◽  
Double Blind

IntroductionEfficacy of conventional repetitive transcranial magnetic stimulation (rTMS) in major depressive disorder (MDD) is limited. The authors report here on an alternative treatment using low energy synchronized TMS (sTMS) at the intrinsic frequency of subjects’ alpha electroencephalogram (EEG).ObjectivesEstablish efficacy and safety profile of sTMS in MDD.Aim(1)Examine the clinical effectiveness of sTMS.(2)Identify adverse effects associated with sTMS.MethodsFifty-two MDD subjects with 17-item Hamilton Depression Rating Scale (HAMD17) scores >17 were enrolled into a randomized, sham controlled, double-blind trial. Current medication remained unchanged during the trial. Depressive symptoms were evaluated by HAMD17 administered weekly.EEGs were recorded at baseline to determine the stimulus frequency and at week 4 to evaluate the physiological effect. sTMS was delivered through three 6000-G cylindrical neodymium magnets synchronously rotating at a rate equal to the subject's intrinsic alpha frequency.ResultsForty-five subjects completed at least 1 week of treatment and were evaluable. Those who received active treatment had superior clinical response to sham (t = 2.54, P = 0.01), where 55.2% in the active treatment group were clinical responders versus 12.5% in sham (X2 = 7.82, P = 0.005). No significant side effects were reported. The clinical improvement was correlated with the degree of EEG improvement (r = .46, P = 0.009).ConclusionsA therapeutic effect in MDD subjects can be achieved through administration of sTMS at the subject's alpha EEG frequency. Because of minimal side effects, this appears to be a safe and effective treatment option.

Variations in responses to a symptom check-list by age, sex, income, residence and ethnicity

1972 ◽  
Vol 7 (3) ◽  
pp. 150-156 ◽  
Author(s):  
F. Engelsmann ◽  
H. B. M. Murphy ◽  
R. Prince ◽  
M. Leduc ◽  
H. Demers
Keyword(s):  
Check List ◽  
Symptom Check List

The Prevalence of Comorbid Anxiety in Schizophrenia, Schizoaffective Disorder and Bipolar Disorder

1998 ◽  
Vol 32 (1) ◽  
pp. 67-72 ◽  
Author(s):  
Susan J. Cosoff ◽  
R. Julian Hafner
Keyword(s):  
Bipolar Disorder ◽  
Anxiety Disorder ◽  
Anxiety Disorders ◽  
Schizoaffective Disorder ◽  
Psychiatric Symptoms ◽  
Psychotic Episode ◽  
Obsessive Compulsive ◽  
General Anxiety ◽  
Admission Rates ◽  
Clinical Benefits

Objective: The aim of this study to determine the prevalence of anxiety disorders in publically treated psychiatric inpatients with a DSM-IV diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder. Method: Using the Structured Clinical Interview for DSM-III-R (SCID), 100 consecutive inpatients with a psychotic disorder were examined for the presence or absence of an anxiety disorder. Questionnaire measures of phobias, obsessive-compulsive and general anxiety symptoms were also applied. Results: The prevalences of social phobia (17%), obsessiv-ompulsive disorder (13%) and generalised anxiety disorder in schizophrenia were relatively high, as were prevalences of obsessive-compulsive (30%) and panic disorder (15%) in bipolar disorder. The proportion of subjects with an anxiety disorder (4345%) was almost identical across the three psychoses, with some evidence of gender differences. Although self-ratings of overall psychiatric symptoms were significantly elevated in those with anxiety disorders, hospital admission rates were not. Conclusions: Almost none of those with anxíeGty disorders were being treated for them, primarily because the severity of the acute psychotic illness required full diagnostic and therapeutic attention. Patients were generally discharged as soon as their psychotic episode was resolved, with little recognition of the presence of an anxiety disorder. Given that anxiety disorders are relatively responsive to treatment, greater awareness of their comorbidity with psychosis should yield worthwhile clinical benefits.

Sign in / Sign up

Export Citation Format

Share Document